This indicates, that therapeutic boosting of only those CTLs that recognise the haematopoiesis restricted mHags HA-1 and HA-2 (HA-1 and HA-2 CTLs) might increase the GvL effect. The risk of graft-versus-host disease (GvHD) will be low because nonhaematopoietic cells will not be recognized. 3 The efficacy of this therapeutic concept is unclear, since a causal relationship between mHag CTL appearance and clinical responses could not yet be made. In vitro assays that show HA-1 and HA-2 CTLs killing leukaemic cells and inhibiting leukaemic progenitor cell outgrowth 3 support the role of mHag CTLs as mediators of the GvL activity. The predictive value of these in vitro assays for the in vivo efficacy of human CTLs is, however, unknown. Compared to the in vitro situation, different cytotoxic mechanisms might be relevant, the accumulation of toxic soluble factors may be different and the time and chance of CTL -target cell interaction might be lower in vivo. Recently, a nonobese diabetic/severe combined immune deficiency (NOD/scid) human leukaemia model has been used to show the antileukaemic efficacy of T-cell therapy in vivo.
4 Allo-HLA T-cell lines served as model for T-cell therapy, but are, due to a high risk of GvHD, clinically not applicable. Here, we used the same NOD/scid mouse leukaemia model to confine the postulated in vivo antileukaemic efficacy of CTLs recognising only a single HLA ligand, the mHag HA-1.
The human leukaemia cells used in this model were derived from the HLA-A2 and HA-1 (HA-1 A2 ) positive patient 'OF' suffering from chronic myeloid leukaemia in lymphoid blast crisis. The latter leukaemia cells were chosen because of their very aggressive progression and minimal growth variation in NOD/scid mice. 4 The CTL lines and clones for adoptive cellular transfer were generated as described. 5 In short, peripheral blood mononuclear cells (PBMCs) of healthy blood donors were stimulated with HA-1 (VLHDDLLEA) or CMV (NLVPMVATV) peptide pulsed dendritic cells and restimulated weekly. The HA-1 CTL line contained 6% HA-1 A2 tetramer positive cells, the CMV CTL line generated with PBMCs from the same donor showed 14% CMV A2 tetramer staining cells (Figure 1a,c) . The HA-1 and CMV CTL clones showed bright staining with the relevant tetramers (Figure 1b,d) . The HA-1 CTL line and clone displayed mHag specific cytotoxicity against OF leukaemia cells (Figure 1e, f) . The CMV CTL line and clone lysed only CMV peptide loaded target cells (Figure 1g,h) .
To evaluate the in vivo antileukaemic efficacy of HA-1 CTLs, NOD/scid mice were inoculated with 10 7 OF leukaemia cells. After 3 days, when the mice were still in a status of minimal disease, 3 Â 10 7 HA-1 CTLs or as control CMV CTLs or PBS were administered intravenously. The mice received interleukin 2 (IL-2) intraperitoneally daily and leukaemia and T cells were monitored in peripheral blood samples weekly as described earlier. 4 Mice receiving the control CMV CTLs or PBS showed no significant difference in leukaemia progression (Figure 2a,b) , hereby excluding non-specific anti-leukaemic effects by the procedure of human CTL infusion. Mice injected with the HA-1 CTL clone showed a significantly delayed leukaemia development (Po0.001, regression analysis using a generalised linear model) by more than 30 (Figure 2a 
We used a leukaemia subtype (i.e. blast crisis of chronic myeloid leukaemia) as disease model that is clinically mostly unresponsive to unselected DLIs. 1 The high in vivo potency of HA-1 CTLs against this leukaemia suggested that enrichment of adoptively transferred lymphocytes for HA-1 CTLs might overcome the limitations of unselected DLI. However, infusion of the HA-1 CTL line was not effective (Figure 2b ). The HA-1 CTL line contained 6% HA-1 CTLs. Thereby, the number of infused HA-1 CTLs was 20-fold lower than with the HA-1 CTL clone (Figure 1a ). This indicates, that the ratio between HA-1 CTLs and leukaemia cells in vivo is relevant for their effective interaction. This hypothesis is supported by the fact that transfer of the HA-1 CTL clone during overt leukaemia was also not effective (Figure 2c) .
Since the HA-1 CTL clone did not entirely prevent the development of progressively growing tumours, immune escape of leukaemia may have occurred. However, leukaemic cells isolated from mice treated with the HA-1 CTL clone were equally sensitive to in vitro killing by HA-1 CTLs as leukaemic cells that had not been passaged in NOD/scid mice (Figure 2f ). Thus, therapy-induced loss of the HA-1 target antigen is unlikely.
Tracking of adoptively transferred CTLs on day 3 after CTL administration showed broad and specificity-independent distribution of these cells in the lung, liver, spleen and bone marrow of the mice (Figure 3a,b) . The involvement of spleen and bone marrow in leukaemic engraftment 4 supports an interaction of the HA-1 CTLs with the leukaemia cells in our model. Thus, the lacking of complete leukaemia eradication may not be caused by the inability of the CTLs to interact with the leukaemia cells in the various organs. On day 10 after HA-1 CTL administration, the CTLs could not be detected anymore in the peripheral blood (Figure 2d,e) . Likewise, beyond 10 days after CTL infusion, also the slopes of leukaemia progression curves (Figure 2a,b) did not differ between the successfully treated and the untreated groups. This indicates absence of Letters to the Editor immunological control during leukaemic progression. IL-2 appeared not sufficient to maintain the administered CTLs in vivo. These results are in accordance with earlier reports in mice 7 and in men 8 showing rapid clearance of mono-or polyclonal CTLs specific for a single epitope. The rapid disappearance of transferred CTLs in our study is not necessarily a problem of the used NOD/scid mouse model. Allo-HLA specific T-cell lines can expand upon antigen recognition in NOD/scid mice. 4 The reason for the better maintenance of the allo-HLA T-cell lines might be found in the different composition and way of generation of these T-cell lines, that is, cotransfer of cytokine producing CD4 T-helper cells and in vitro CTL distribution in vivo. Relevant mice were sacrificed 3 days after the treatment with the HA-1 CTL clone (a) and CMV CTL clone (b). Lymphocytes were enriched from peripheral blood and organ suspensions by ficoll gradient. Depicted are human CD3 (X-axis) and mouse Ly-5 (Y-axis) staining of peripheral blood and organ suspensions of representative mice.
Letters to the Editor stimulation against multiple (unknown) epitopes that are present in vivo. We are currently investigating the putative supportive roles of cotransferred nontumour reactive CD4 T-helper cells in combination with professional antigen presenting cells in mHag specific CTL responses against tumours.
In conclusion, we provide the first direct evidence for in vivo interaction of human CTLs specific for only one mHag HA-1 leading to human leukaemia eradication. Our results show the crucial role of numbers and maintenance of HA-1 CTLs in the antileukaemic effector phase of human mHag specific CTLs in vivo. The overall limited persistence of adoptively transferred CTLs is a crucial starting point for improvements of cellular adoptive immunotherapy. Our findings are important for the rationale to apply mHag HA-1-specific immunotherapy of leukaemia in men either by adoptive cellular transfer and/or by mHag HA-1 peptide vaccination.
